Head-To-Head Review: Inovio Pharmaceuticals (NASDAQ:INO) and Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ)

Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ – Get Rating) and Inovio Pharmaceuticals (NASDAQ:INO – Get Rating) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability and analyst recommendations.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Health Sciences Acquisitions Co. 2 and Inovio Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Health Sciences Acquisitions Co. 2	0	0	0	0	N/A
Inovio Pharmaceuticals	1	3	0	0	1.75

Inovio Pharmaceuticals has a consensus target price of $2.00, indicating a potential upside of 229.76%. Given Inovio Pharmaceuticals’ higher probable upside, analysts clearly believe Inovio Pharmaceuticals is more favorable than Health Sciences Acquisitions Co. 2.

Profitability

This table compares Health Sciences Acquisitions Co. 2 and Inovio Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Health Sciences Acquisitions Co. 2	N/A	N/A	-2.38%
Inovio Pharmaceuticals	-2,371.71%	-97.93%	-65.84%

Institutional & Insider Ownership

89.7% of Health Sciences Acquisitions Co. 2 shares are owned by institutional investors. Comparatively, 46.4% of Inovio Pharmaceuticals shares are owned by institutional investors. 21.9% of Health Sciences Acquisitions Co. 2 shares are owned by company insiders. Comparatively, 2.0% of Inovio Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Risk and Volatility

Health Sciences Acquisitions Co. 2 has a beta of 0.09, suggesting that its stock price is 91% less volatile than the S&P 500. Comparatively, Inovio Pharmaceuticals has a beta of 1.07, suggesting that its stock price is 7% more volatile than the S&P 500.

Earnings & Valuation

This table compares Health Sciences Acquisitions Co. 2 and Inovio Pharmaceuticals’ top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Health Sciences Acquisitions Co. 2	N/A	N/A	-$380,000.00	N/A	N/A
Inovio Pharmaceuticals	$10.26 million	15.53	-$279.82 million	($0.98)	-0.62

Health Sciences Acquisitions Co. 2 has higher earnings, but lower revenue than Inovio Pharmaceuticals.

Summary

Health Sciences Acquisitions Co. 2 beats Inovio Pharmaceuticals on 6 of the 9 factors compared between the two stocks.

About Health Sciences Acquisitions Co. 2

(Get Rating)

Health Sciences Acquisitions Corporation 2 does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or related business combination with one or more businesses in the biopharma and medical technology sectors in North America or Europe. Health Sciences Acquisitions Corporation 2 was incorporated in 2020 and is based in New York, New York.

About Inovio Pharmaceuticals

(Get Rating)

Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Its product pipeline includes VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.